Basisstatistiken
| LEI | 549300I1PJXVT7ISIV91 |
| CIK | 1505497 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioRestorative Therapies, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 29, 2026 |
EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made as of May 27, 2026 (the “Effective Date”), by and between BioRestorative Therapies, Inc. |
|
| May 29, 2026 | ||
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 26, 2026 (Date of earliest event reported) BIORESTORATIVE THERAPIES, INC. |
|
| May 29, 2026 |
EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made as of May 27, 2026 (the “Effective Date”), by and between BioRestorative Therapies, Inc. |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERA |
|
| May 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 1, 2026 (Date of earliest event reported) BIORESTORATIVE THERAPIES, INC. |
|
| April 30, 2026 |
Up to 15,285,715 Shares of Common Stock Underlying Outstanding Warrants Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-293322 PROSPECTUS Up to 15,285,715 Shares of Common Stock Underlying Outstanding Warrants This prospectus relates to 14,285,715 shares of our common stock issuable upon the exercise of our outstanding warrants issued in February 2026 (the “Common Stock Warrants”). The Common Stock Warrants were offered and sold by us pursuant to a pro |
|
| April 27, 2026 |
As filed with the Securities and Exchange Commission on April 27, 2026. As filed with the Securities and Exchange Commission on April 27, 2026. Registration No. 333-293322 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIORESTORATIVE THERAPIES, INC. (Exact name of registrant as specified in its charter) Nevada 8099 30-1341024 |
|
| April 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 23, 2026 (Date of earliest event reported) BIORESTORATIVE THERAPIES, INC. |
|
| April 23, 2026 | ||
| April 20, 2026 |
Calculation of Filing Fee Tables S-1 BioRestorative Therapies, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| April 20, 2026 |
As filed with the Securities and Exchange Commission on April 20, 2026. As filed with the Securities and Exchange Commission on April 20, 2026. Registration No. 333-293322 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIORESTORATIVE THERAPIES, INC. (Exact name of registrant as specified in its charter) Nevada 8099 30-1341024 (State or other ju |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, Fo |
|
| April 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, Fo |
|
| March 26, 2026 |
BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN ARTICLE 1 Exhibit 10.7 As Amended September 18, 2025 BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN ARTICLE 1 PURPOSE The purpose of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “Plan”) is to promote the success and enhance the value of BioRestorative Therapies, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (as defined below) by linking the individual inte |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37603 BIORESTORATIVE THERAPIES |
|
| February 17, 2026 |
BioRestorative Announces Closing of $5.0 Million Public Offering Exhibit 99.2 BioRestorative Announces Closing of $5.0 Million Public Offering MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) - BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14, |
|
| February 17, 2026 |
BioRestorative Announces Pricing of $5.0 Million Public Offering Exhibit 99.1 BioRestorative Announces Pricing of $5.0 Million Public Offering MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) - BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the pricing of a public offering of 14,285,715 shares of commo |
|
| February 17, 2026 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT February 11, 2026 Mr. Lance Alstodt President, Chief Executive Officer and Chairman of the Board BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, NY 11747 Dear Mr. Alstodt: This agreement (the “Agreement”) constitutes the agreement between Rodman & Renshaw LLC (“Rodman” or the “Placement Agent”) and BioRestorative Therapies, Inc. (the “Com |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 11, 2026 (Date of earliest event reported) BIORESTORATIVE THERAPIES, INC. |
|
| February 13, 2026 |
Filed pursuant to Rule 424(b)(4) Registration Statement No. 333-293322 PROSPECTUS Up to 14,285,715 Units, each consisting of: One Share of Common Stock or One Pre-Funded Warrant to Purchase One Share of Common Stock and One Common Stock Warrant to Purchase up to One Share of Common Stock Up to 14,285,715 Shares of Common Stock or Shares of Common Stock Underlying Pre-Funded Warrants Up 14,285,715 |
|
| February 10, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| February 10, 2026 |
As filed with the Securities and Exchange Commission on February 10, 2026. As filed with the Securities and Exchange Commission on February 10, 2026. Registration No. 333-293322 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIORESTORATIVE THERAPIES, INC. (Exact name of registrant as specified in its charter) Nevada 8099 30-1341024 (State or other jurisdiction of ( |
|
| February 10, 2026 |
Exhibit 10.51 PLACEMENT AGENCY AGREEMENT February , 2026 Mr. Lance Alstodt President, Chief Executive Officer and Chairman of the Board BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, NY 11747 Dear Mr. Alstodt: This agreement (the “Agreement”) constitutes the agreement between Rodman & Renshaw LLC (“Rodman” or the “Placement Agent”) and BioRestorative Therapies, Inc. (the “Comp |
|
| February 9, 2026 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BioRestorative Therapies, Inc. Exhibit 4.4 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BioRestorative Therapies, Inc. Warrant Shares: Initial Exercise Date: [], 2026 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| February 9, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| February 9, 2026 |
PREFUNDED COMMON STOCK PURCHASE WARRANT BioRestorative Therapies, Inc. Exhibit 4.3 PREFUNDED COMMON STOCK PURCHASE WARRANT BioRestorative Therapies, Inc. Warrant Shares: Initial Exercise Date: [], 2026 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| February 9, 2026 |
Exhibit 10.50 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February [], 2026, between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and c |
|
| February 9, 2026 |
COMMON STOCK PURCHASE WARRANT BioRestorative Therapies, Inc. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT BioRestorative Therapies, Inc. Warrant Shares: Initial Exercise Date: [], 2026 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Ini |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026. As filed with the Securities and Exchange Commission on February 9, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIORESTORATIVE THERAPIES, INC. (Exact name of registrant as specified in its charter) Nevada 8099 30-1341024 (State or other jurisdiction of (Primary Standard Industri |
|
| December 19, 2025 |
Confidentially submitted to the Securities and Exchange Commission on December 19, 2025. |
|
| December 12, 2025 |
508,592 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-291623 PROSPECTUS 508,592 Shares of Common Stock This prospectus relates to the offer and sale from time to time of up to 508,592 shares of common stock, par value $0.0001 per share, of BioRestorative Therapies, Inc. by the selling securityholders listed under the caption “Selling Securityholders” on page 7 of this prospectus (the “selling secu |
|
| December 8, 2025 |
BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 December 8, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: BioRestorative Therapies, Inc. Registration Statement on Form S-1 Filed November 18, 2025 File No. 333-291623 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Ac |
|
| November 18, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| November 18, 2025 |
As filed with the Securities and Exchange Commission on November 18, 2025 As filed with the Securities and Exchange Commission on November 18, 2025 Registration No. |
|
| November 18, 2025 |
Exhibit 10.49 October 15, 2025 Auctus Fund, LLC 545 Boylston Street, 2nd Floor Boston, Massachusetts, 02116 Gentlemen: Reference is made to the Common Stock Purchase Warrant, dated October 8, 2025, issued by BioRestorative Therapies, Inc. (the “Company”) to Auctus Fund, LLC (“Auctus”) for the purchase of up to 187,500 shares of common stock of the Company (the “Warrant”). The parties understand th |
|
| November 18, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| November 18, 2025 |
As filed with the Securities and Exchange Commission on November 18, 2025 As filed with the Securities and Exchange Commission on November 18, 2025 Registration No. |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE T |
|
| November 12, 2025 |
Exhibit 99.1 |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Com |
|
| October 9, 2025 |
X0708 D LIVE 0001505497 BioRestorative Therapies, Inc. 40 Marcus Drive Suite One Melville NY NEW YORK 11747 631-760-8100 NEVADA Traxxec Inc. Columbia River Resources Inc. Stem Cell Assurance, Inc. Corporation true Lance Alstodt c/o 40 Marcus Drive Suite One Melville NY NEW YORK 11747 Director Executive Officer Francisco Silva c/o 40 Marcus Drive Suite One Melville NY NEW YORK 11747 Director Execut |
|
| October 8, 2025 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT Date: , 2025 BioRestorative Therapies, Inc. 40 Marcus Drive, Suite 1 Melville, New York 11747 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), as follows: 1. This Subscription Agreement, including the Investor Information attached hereto as Annex A (col |
|
| October 8, 2025 |
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market Exhibit 99.1 BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market MELVILLE, N.Y., October 6, 2025 — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into definitive agreements with several accredited and/or institutional |
|
| October 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 6, 2025 (Date of earliest event reported) BIORESTORATIVE THERAPIES, INC. |
|
| October 8, 2025 |
COMMON STOCK PURCHASE WARRANT BIORESTORATIVE THERAPIES, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| October 8, 2025 |
BioRestorative Therapies, Inc. 678,125 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269631 PROSPECTUS SUPPLEMENT (To Prospectus dated February 14, 2023) BioRestorative Therapies, Inc. 678,125 Shares of Common Stock We are offering to a limited number of investors 678,125 shares of our common stock, par value $0.0001 per share (“common stock”). In a concurrent private placement (the “Warrant Private Placement”), we are also sel |
|
| October 8, 2025 |
[Remainder of page intentionally left blank. Signature page follows.] Exhibit 10.2 STRICTLY PRIVATE AND CONFIDENTIAL August 11, 2025 BioRestorative Therapies, Inc. Attn: Lance Alstodt, Chief Executive Officer 40 Marcus Drive, Suite One, Melville, New York 11747 Dear Lance: BioRestorative Therapies, Inc. (together with any present and future subsidiaries and affiliates of BioRestorative Therapies, Inc., the “Company”) hereby retains Alere Financial Partners (a divisi |
|
| October 6, 2025 |
Up to $1,017,040 BioRestorative Therapies, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269631 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS SUPPLEMENT DATED NOVEMBER 6, 2024 (To Prospectus dated February 14, 2023) Up to $1,017,040 BioRestorative Therapies, Inc. Common Stock This Supplement No. 1, or this Supplement, modifies and amends, only to the extent indicated herein, certain information contained in our prospectus supplement, d |
|
| September 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 18, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Co |
|
| August 14, 2025 |
Exhibit 99.1 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commi |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commi |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERAP |
|
| August 12, 2025 |
Press release, dated August 12, 2025, issued by BioRestorative Therapies, Inc. Exhibit 99.1 |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commiss |
|
| June 13, 2025 |
Exhibit 99.1 BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease – The International Society for Stem Cell Research (“ISSCR”) 2025 Annual Meeting is the world’s foremost gathering of stem cell and regenerative medicine leaders – – Updated data presented at ISSCR 2025 demonstrates >50% improvement in |
|
| June 13, 2025 |
Exhibit 99.2 |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERA |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commissi |
|
| May 14, 2025 |
Exhibit 99.1 |
|
| April 21, 2025 |
Exhibit 16 April 21, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by BioRestorative Therapies, Inc. under Item 4.01 of its Form 8-K dated April 16, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of BioRestorative Therapies, |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commis |
|
| March 28, 2025 |
Exhibit 10.41 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 14, 2025 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Francisco Silva (the “Participant”). Grant Date: February 14, 2025 Exercise Pri |
|
| March 28, 2025 |
BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as amended* Exhibit 10.7 As Amended September 19, 2024 BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN ARTICLE 1 PURPOSE The purpose of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “Plan”) is to promote the success and enhance the value of BioRestorative Therapies, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (as defined below) by linking the individual inte |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37603 BIORESTORATIVE THERAPIES |
|
| March 28, 2025 |
Exhibit 19 BIORESTORATIVE THERAPIES, INC. INSIDER TRADING POLICY Effective March 27, 2025 I. Introduction The purpose of this Insider Trading Policy (the “Policy”) is to promote compliance with applicable securities laws by BioRestorative Therapies, Inc. and its subsidiaries (the “Company”) and all directors, officers and employees thereof, and consultants thereto, in order to preserve the reputat |
|
| March 28, 2025 |
Exhibit 10.40 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 14, 2025 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Lance Alstodt (the “Participant”). Grant Date: February 14, 2025 Exercise Price |
|
| March 28, 2025 |
Exhibit 10.44 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 14, 2025 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Patrick F. Williams (the “Participant”). Grant Date: February 14, 2025 |
|
| March 28, 2025 |
Exhibit 10.42 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 14, 2025 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Robert Kristal (the “Participant”). Grant Date: February 14, 2025 Exercise Pric |
|
| March 28, 2025 |
Exhibit 10.43 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 14, 2025 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Nickolay Kukekov (the “Participant”). Grant Date: February 14, 2025 Exe |
|
| March 28, 2025 |
Exhibit 10.45 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 14, 2025 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and David Rosa (the “Participant”). Grant Date: February 14, 2025 Exercise |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commis |
|
| March 27, 2025 |
Exhibit 99.1 |
|
| February 19, 2025 |
EX-99.1 2 ex991.htm INCENTIVE STOCK OPTION AWARD AGREEMENT INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 14, 2025 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Lance Alstodt (the “Participant”). |
|
| February 19, 2025 |
EX-99.1 2 ex991.htm INCENTIVE STOCK OPTION AWARD AGREEMENT INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 14, 2025 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Francisco Silva (the “Participant” |
|
| February 10, 2025 |
Exhibit 99.1 |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2025 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Com |
|
| February 10, 2025 |
Exhibit 99.2 |
|
| November 14, 2024 |
BRTX / BioRestorative Therapies, Inc. / Auctus Fund Management Llc begin 644 brtxex1.pdf M)5!$1BTQ+C8-)>+CS],-"C,R(# @;V)J#3P\+TQI;F5A.()8XD-!E!1(QJ@Q,C SK0>H8&(DAC.>^ $08 XPPXH#0IE;F1S=')E M86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HV," P M(&]B:@T\/"]#(#DR+T9I;'1E7!E+U!A9V4^/@UE;F1O8FH-,S4@,"!O8FH-/#PO1FEL M=&5R+T9L871E1&5C;V1E+T9I/9JBWOS.GL]NG0YE$8[1M!6-M=C=N0OMAPY=%5T:1 MJ<.=I;UGPTC,61@.;]M?EW.?RL.V3&EV7R-[2&$J9MX:E%E]?BUCT% [email protected]%SDY'Y3.C3 |
|
| November 13, 2024 |
Ex 99.1 BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update MELVILLE, N.Y., November 12, 2024 (GLOBE NEWSWIRE) - BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the third quarter ended Sept |
|
| November 13, 2024 |
As filed with the Securities and Exchange Commission on November 13, 2024 As filed with the Securities and Exchange Commission on November 13, 2024 Registration No. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Com |
|
| November 13, 2024 |
Ex 99.3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
|
| November 13, 2024 |
Ex 107 Calculation of Filing Fee Table FORM S-8 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| November 13, 2024 |
Ex 99.2 BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data – Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in function – – If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Se |
|
| November 12, 2024 |
BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as amended Exhibit 10.1 As Amended September 19, 2024 BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN ARTICLE 1 PURPOSE The purpose of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “Plan”) is to promote the success and enhance the value of BioRestorative Therapies, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (as defined below) by linking the individual inte |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE T |
|
| November 7, 2024 |
Exhibit 99.1 |
|
| November 7, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Comm |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Comm |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37603 BIORES |
|
| November 6, 2024 |
Up to $3,614,170 BioRestorative Therapies, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269631 PROSPECTUS SUPPLEMENT (To Prospectus dated February 14, 2023) Up to $3,614,170 BioRestorative Therapies, Inc. Common Stock We have entered into an At The Market Offering Agreement, or the Sales Agreement, with Rodman & Renshaw LLC, or the Agent, relating to the sale of shares of our common stock, par value $0.0001 per share, or the commo |
|
| November 6, 2024 |
AT THE MARKET OFFERING AGREEMENT November 6, 2024 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, NY 10022 Ladies and Gentlemen: BioRestorative Therapies, Inc. |
|
| November 6, 2024 |
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934. * Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of November 5, 2024, BioRestorative Therapies, Inc. (“we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Act of 1934, as amended: our common stock, $0.0001 par value per share (the “common stock”). The following summary of our capital stock does n |
|
| September 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Co |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERAP |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commi |
|
| August 13, 2024 | ||
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| August 6, 2024 | ||
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commis |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37603 BIORES |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERA |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commissi |
|
| May 24, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commissi |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-37603 CUSIP NUMBER 090655606 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: March 31, 2024 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report |
|
| April 19, 2024 |
2,513,686 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-278488 PROSPECTUS 2,513,686 Shares of Common Stock This prospectus relates to the offer and sale from time to time of up to 2,513,686 shares of common stock, par value $0.0001 per share, of BioRestorative Therapies, Inc. by the selling securityholders listed under the caption “Selling Securityholders” on page 7 of this prospectus, or the sellin |
|
| April 17, 2024 |
BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 April 17, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: BioRestorative Therapies, Inc. Registration Statement on Form S-1 Filed April 3, 2024 File No. 333-278488 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1 |
|
| April 12, 2024 |
As filed with the Securities and Exchange Commission on April 12, 2024 As filed with the Securities and Exchange Commission on April 12, 2024 Registration No. |
|
| April 11, 2024 |
United States securities and exchange commission logo April 11, 2024 Lance Alstodt President and Chief Executive Officer BioRestorative Therapies, Inc. |
|
| April 3, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 1, 2024 |
Exhibit 10.42 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and David Rosa (the “Participant”). Grant Date: February 13, 2024 Exercise |
|
| April 1, 2024 |
Exhibit 10.38 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Robert Kristal (the “Participant”). Grant Date: February 13, 2024 Exercise Pric |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37603 BIORESTORATIVE THERAPIES |
|
| April 1, 2024 |
Exhibit 10.40 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Nickolay Kukekov (the “Participant”). Grant Date: February 13, 2024 Exe |
|
| April 1, 2024 |
Exhibit 10.27 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made as of December , 2021 (the “Effective Date”), by and between BioRestorative Therapies, Inc., a Delaware corporation (the “Company”), and Robert Paccasassi (the “Executive”) (Company and Executive are collectively the “Parties”). Certain capitalized terms used in this Agreement are defined in |
|
| April 1, 2024 |
Exhibit 10.12 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made as of November 4, 2021 (the “Effective Date”), by and between BioRestorative Therapies, Inc., a Delaware corporation (the “Company”), and Robert E. Kristal (the “Executive”) (Company and Executive are collectively the “Parties”). Certain capitalized terms used in this Agreement are defined i |
|
| April 1, 2024 |
Exhibit 10.36 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Lance Alstodt (the “Participant”). Grant Date: February 13, 2024 Exercise Price |
|
| April 1, 2024 |
Exhibit 10.41 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Patrick F. Williams (the “Participant”). Grant Date: February 13, 2024 |
|
| April 1, 2024 |
BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as amended* Exhibit 10.7 As Amended September 13, 2023 BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN ARTICLE 1 PURPOSE The purpose of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “Plan”) is to promote the success and enhance the value of BioRestorative Therapies, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (as defined below) by linking the individual inte |
|
| April 1, 2024 |
Exhibit 97 BIORESTORATIVE THERAPIES, INC. CLAWBACK POLICY 1. Purpose. The Board of Directors (the “Board”) of BioRestorative Therapies, Inc. (the “Company”) has adopted this clawback policy, as amended (the “Clawback Policy”), which describes the circumstances in which Covered Individuals will be required to repay or return Erroneously Awarded Compensation to the Company in the event of an Account |
|
| April 1, 2024 |
Exhibit 10.39 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Robert Paccasassi (the “Participant”). Grant Date: February 13, 2024 Exercise P |
|
| April 1, 2024 |
Exhibit 10.37 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Francisco Silva (the “Participant”). Grant Date: February 13, 2024 Exercise Pri |
|
| March 12, 2024 |
BioRestorative Therapies to Participate in the 36 BioRestorative Therapies to Participate in the 36th Annual ROTH Conference MELVILLE, N. |
|
| March 12, 2024 | ||
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commis |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $.0001 Par Value (Title of Class of Securities) 090655606 (CUSIP Number) Dale Broadrick 3003 Brick Church Pike Nashville, TN 37207 (615) 256-0600 (Name, Address and Telephone Number of Person |
|
| February 15, 2024 |
EX-1 2 ex1.htm STOCK OPTION AGREEMENT INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Lance Alstodt (the “Participant”). Grant Date: February |
|
| February 15, 2024 |
SC 13D/A 1 sc13da2.htm SCHEDULE 13D AMENDMENT 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $.0001 Par Value (Title of Class of Securities) 090655606 (CUSIP Number) Lance Alstodt 40 Marcus Drive Suite One Melville, New York 11747 (631) |
|
| February 15, 2024 |
SC 13D/A 1 sc13da2.htm SCHEDULE 13D/AMENDMENT 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $.0001 Par Value (Title of Class of Securities) 090655606 (CUSIP Number) Francisco Silva 40 Marcus Drive Suite One Melville, New York 11747 (631 |
|
| February 15, 2024 |
EX-1 2 ex1.htm STOCK OPTION AGREEMENT INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 13, 2024 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Francisco Silva (the “Participant”). Grant Date: Februa |
|
| February 14, 2024 |
US0906556065 / Biorestorative Therapies Inc / Auctus Fund Management Llc Passive Investment SC 13G/A 1 brtx13gv2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 090655606 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Comm |
|
| February 8, 2024 |
Form of New Warrant issued to Auctus Fund, LLC NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| February 8, 2024 |
Form of Agreement, dated February 5, 2024, by and between the Company and Auctus Fund, LLC February 5, 2024 Auctus Fund, LLC 545 Boylston Street, 2nd Floor Boston, MA 02116 Re: Reprice and Reload Offer of Common Stock Purchase Warrants To Whom It May Concern: BioRestorative Therapies, Inc. |
|
| February 8, 2024 |
Form of New Warrant issued to warrantholders (other than Auctus Fund, LLC) NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| February 8, 2024 |
February 6, 2024 [Name and address of warrant holder] Re: Reprice and Reload Offer of Common Stock Purchase Warrants To Whom It May Concern: BioRestorative Therapies, Inc. |
|
| February 8, 2024 |
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8. |
|
| February 5, 2024 |
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease — Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N. |
|
| February 5, 2024 | ||
| February 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Comm |
|
| February 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2024 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Comm |
|
| February 1, 2024 | ||
| November 15, 2023 |
Calculation of Filing Fee Table FORM S-8 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| November 15, 2023 |
As filed with the Securities and Exchange Commission on November 15, 2023 As filed with the Securities and Exchange Commission on November 15, 2023 Registration No. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE T |
|
| September 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2023 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Co |
|
| August 23, 2023 |
$6,109,000 BioRestorative Therapies, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269631 SUPPLEMENT NO. 3 TO PROSPECTUS SUPPLEMENT DATED APRIL 14, 2023 (To Prospectus dated February 14, 2023) $6,109,000 BioRestorative Therapies, Inc. Common Stock This Supplement No. 3, or this Supplement, modifies and amends, only to the extent indicated herein, certain information contained in our prospectus supplement, dated April 14, 2023 |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERAP |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| July 13, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2023, between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| July 13, 2023 |
BioRestorative Therapies, Inc. 685,033 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269631 PROSPECTUS SUPPLEMENT (To Prospectus dated February 14, 2023) BioRestorative Therapies, Inc. 685,033 Shares of Common Stock We are offering to a limited number of institutional buyers and accredited investors 685,033 shares of our common stock, par value $0.0001 per share (“common stock”). We have retained Titan Partners Group LLC, a div |
|
| July 13, 2023 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT [, 2023 BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 Attention: Lance Alstodt, President and Chief Executive Officer Dear Mr. Alstodt: This agreement (the “Agreement”) constitutes the agreement between Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Placement Agent”) and BioRestorative Therap |
|
| July 13, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2023 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commiss |
|
| July 13, 2023 |
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering Exhibit 99.1 BioRestorative Therapies Announces $2.1 Million Registered Direct Offering MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) - BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a definitive agreement with several accredited and institutional investor |
|
| July 11, 2023 |
$4,200,000 BioRestorative Therapies, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269631 SUPPLEMENT NO. 2 TO PROSPECTUS SUPPLEMENT DATED APRIL 14, 2023 (To Prospectus dated February 14, 2023) $4,200,000 BioRestorative Therapies, Inc. Common Stock This Supplement No. 2, or this Supplement, modifies and amends, only to the extent indicated herein, certain information contained in our prospectus supplement, dated April 14, 2023 |
|
| May 15, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-269631 SUPPLEMENT NO. 1 TO PROSPECTUS SUPPLEMENT DATED APRIL 14, 2023 (To Prospectus dated February 14, 2023) $5,365,000 BioRestorative Therapies, Inc. Common Stock This Supplement No. 1, or this Supplement, modifies and amends, only to the extent indicated herein, certain information contained in our prospectus supplement, dated April 14, 2023 |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERA |
|
| April 14, 2023 |
Exhibit 1.1 BIORESTORATIVE THERAPIES, INC. Common Stock ($0.0001 par value per share) Capital on Demand™ Sales Agreement April 14, 2023 JonesTrading Institutional Services LLC 211 East 43rd Street, 15th Floor New York, NY 10017 Ladies and Gentlemen: BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Servic |
|
| April 14, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 14, 2023 (Date of earliest event reported) BIORESTORATIVE THERAPIES, INC. |
|
| April 14, 2023 |
Filed Pursuant to Rule 424(b)(2) Registration No. 333-269631 PROSPECTUS SUPPLEMENT (To Prospectus dated February 14, 2023) $3,700,000 BioRestorative Therapies, Inc. Common Stock We have entered into a Capital on Demand™ Sales Agreement, or the Sales Agreement, with JonesTrading Institutional Services LLC, or the Agent, relating to the sale of shares of our common stock offered by this prospectus s |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 6, 2023 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37603 30-1341024 (State or other jurisdiction of incorporation) (Commiss |
|
| March 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 27, 2023 |
Exhibit 10.33 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Patrick Williams (the “Participant”). Grant Date: February 17, 2023 Exe |
|
| March 27, 2023 |
Exhibit 10.4 BIORESTORATIVE THERAPIES, INC. 40 Marcus Drive Melville, New York 11747 November 21, 2022 Regenerative Sciences, LLC Regenexx, LLC 403 Summit Blvd., Suite 201 Broomfield, Colorado 80021 Re: License Agreement Gentlemen: Reference is made to the License Agreement, dated as of January 27, 2012, between BioRestorative Therapies, Inc. (“BRT”) and Regenerative Sciences, LLC (“RSI”), as amen |
|
| March 27, 2023 |
Exhibit 10.30 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Robert Kristal (the “Participant”). Grant Date: February 17, 2023 Exercise Pric |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37603 BIORESTORATIVE THERAPIES |
|
| March 27, 2023 |
Exhibit 10.28 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Lance Alstodt (the “Participant”). Grant Date: February 17, 2023 Exercise Price |
|
| March 27, 2023 |
Exhibit 10.31 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Robert Paccasassi (the “Participant”). Grant Date: February 17, 2023 Exercise P |
|
| March 27, 2023 |
Exhibit 10.32 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Nickolay Kukekov (the “Participant”). Grant Date: February 17, 2023 Exe |
|
| March 27, 2023 |
BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as amended* Exhibit 10.7 As Amended November 3, 2022 BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN ARTICLE 1 PURPOSE The purpose of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “Plan”) is to promote the success and enhance the value of BioRestorative Therapies, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (as defined below) by linking the individual intere |
|
| March 27, 2023 |
Exhibit 10.34 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Non-Qualified Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and David Rosa (the “Participant”). Grant Date: February 17, 2023 Exercise |
|
| March 27, 2023 |
Exhibit 10.29 INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Francisco Silva (the “Participant”). Grant Date: February 17, 2023 Exercise Pri |
|
| February 17, 2023 |
EX-1 2 ex1.htm STOCK OPTION AGREEMENT INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Lance Alstodt (the “Participant”). Grant Date: February |
|
| February 17, 2023 |
EX-1 2 ex1.htm STOCK OPTION AGREEMENT INCENTIVE STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Incentive Stock Option Award Agreement (this “Agreement”) is made and entered into as of February 17, 2023 by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Francisco Silva (the “Participant”). Grant Date: Februa |
|
| February 17, 2023 |
BRTX / BioRestorative Therapies Inc / ALSTODT LANCE - AMENDMENT 1 Activist Investment SC 13D/A 1 sc13da1.htm AMENDMENT 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $.0001 Par Value (Title of Class of Securities) 090655408 (CUSIP Number) Lance ALstodt 40 Marcus Drive Suite One Melville, New York 11747 (631) 760-8100 (Nam |
|
| February 17, 2023 |
BRTX / BioRestorative Therapies Inc / Silva Francisco - AMENDMENT 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $.0001 Par Value (Title of Class of Securities) 090655408 (CUSIP Number) Francisco Silva 40 Marcus Drive Suite One Melville, New York 11747 (631) 760-8100 (Name, Address and Telephone Number o |
|
| February 14, 2023 |
US0906556065 / Biorestorative Therapies Inc / Auctus Fund Management Llc Passive Investment SC 13G/A 1 BRTX13g22v5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 090655606 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 13, 2023 |
As filed with the Securities and Exchange Commission on February 13, 2023 As filed with the Securities and Exchange Commission on February 13, 2023 Registration No. |
|
| February 13, 2023 |
BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11743 CORRESP 1 filename1.htm BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11743 February 13, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: BioRestorative Therapies, Inc. Registration Statement on Form S-3 Filed February 7, 2023 File No. 333-269631 Ladies and Gentlemen: Pursuant to Rule 461 |
|
| February 13, 2023 |
EX-4.1 2 ex41.htm FORM OF INDENTURE Exhibit 4.1 BIORESTORATIVE THERAPES, INC. TO , TRUSTEE FORM OF INDENTURE Dated as of Debt Securities CROSS REFERENCE SHEET Between Provisions of Sections 310 through 318(a) inclusive of the Trust Indenture Act of 1939 and the Indenture dated as of , between BioRestorative Therapies, Inc. and , as trustee. Section of Act Section of Indenture 310(a)(1) and (2) 8.0 |
|
| February 10, 2023 |
United States securities and exchange commission logo February 10, 2023 Lance Alstodt President and Chief Executive Officer BioRestorative Therapies, Inc. |
|
| February 7, 2023 |
As filed with the Securities and Exchange Commission on February 7, 2023 As filed with the Securities and Exchange Commission on February 7, 2023 Registration No. |
|
| February 7, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| February 7, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 090655606 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| January 5, 2023 | ||
| January 5, 2023 |
BIORESTORATIVE THERAPIES, INC. AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (?Agreement?), dated as of December 23, 2022, is entered into by and between BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and BioRestorative Therapies, Inc., a Nevada corporation and a wholly-owned subsidiary of the Company (?NewCo?). WHEREAS, the Company, whose shares of common |
|
| January 5, 2023 |
EX-3.2 4 ex32.htm ARTICLES OF MERGER RE NEVADA |
|
| January 5, 2023 |
BYLAWS OF BIORESTORATIVE THERAPIES, INC. ARTICLE I Offices, Corporate Seal Section 1.01 Offices. BioRestorative Therapies, Inc. (the ?Corporation?) shall have a registered office, a principal office and such other offices as the board of directors of the Corporation (the ?Board of Directors?) may determine. Section 1.02 Corporate Seal. The Board of Directors may provide a suitable seal, containing |
|
| January 5, 2023 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2022 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37603 91-1835664 (State or other jurisdiction of incorporation) (C |
|
| January 5, 2023 |
EX-3.1 3 ex31.htm CERTIFICATE OF MERGER RE DELAWARE |
|
| January 5, 2023 | ||
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE T |
|
| November 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37603 91-1835664 (State or other jurisdiction of incorporation) (Co |
|
| September 30, 2022 |
As filed with the Securities and Exchange Commission on September 30, 2022 As filed with the Securities and Exchange Commission on September 30, 2022 Registration No. |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2022 BioRestorative Therapies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37603 91-1835664 (State or other jurisdiction of incorporation) (C |
|
| September 13, 2022 | ||
| September 13, 2022 |
Certificate of Designation of Preferred Stock (Series B) BIORESTORATIVE THERAPIES, INC. Certificate of Designations of Preferred Stock Authorized by Resolution of the Board of Directors Providing for an Issue of 1,543,158 Shares of Preferred Stock Designated ?Series B Preferred Stock.? BioRestorative Therapies, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware, in accordance with th |
|
| September 13, 2022 | ||
| August 16, 2022 |
POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on August 16, 2022 Registration No. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERAP |
|
| August 5, 2022 |
PRE 14A 1 proxystmt.htm 2022 ANNUAL MEETING PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check |
|
| July 14, 2022 |
US0906556065 / Biorestorative Therapies Inc / Auctus Fund Management Llc Passive Investment SC 13G 1 BRTX13g22v1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 090655606 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| June 23, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-265052 Filed Pursuant to Rule 424(b)(3) Registration No. 333-265052 PROSPECTUS 1,856,938 Shares of Common Stock This prospectus relates to the offer and sale from time to time of up to 1,856,938 shares of common stock, par value $0.0001 per share, of BioRestorative Therapies, Inc. by the selling securityholders listed under the caption ?Selling Securityholders? on page 6 of this prospectus, or the sellin |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $.0001 Par Value (Title of Class of Securities) 090655606 (CUSIP Number) Dale Broadrick 3003 Brick Church Pike Nashville, TN 37207 (615) 256-0600 (Name, Address and Telephone Number of Person |
|
| June 13, 2022 |
BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 June 13, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: BioRestorative Therapies, Inc. Registration Statement on Form S-3 Filed May 18, 2022 File No. 333-265052 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 193 |
|
| May 20, 2022 |
United States securities and exchange commission logo May 20, 2022 Lance Alstodt Chief Executive Officer BioRestorative Therapies, Inc. |
|
| May 18, 2022 |
ex 4.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into effective as of January 20, 2022 (the ?Effective Date?), among BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and (the ?Holder?). RECITALS: WHEREAS, pursuant to an exchange agreement entered into by and between the Company and the Holder, dated as of , 2021 ( |
|
| May 18, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) BIORESTORATIVE THERAPIES, INC. |
|
| May 18, 2022 |
As filed with the Securities and Exchange Commission on May 18, 2022 As filed with the Securities and Exchange Commission on May 18, 2022 Registration No. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE THERA |
|
| April 7, 2022 |
SC 13D/A 1 sc13da7.htm DALE BROADRICK SCHEDULE 13D AMENDMENT 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $.0001 Par Value (Title of Class of Securities) 090655606 (CUSIP Number) Dale Broadrick 3003 Brick Church Pike Nashville, TN 3720 |
|
| March 30, 2022 |
Exhibit 10.18 AMENDMENT NO. 1 TO NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Amendment No. 1 to Non-Qualified Stock Option Award Agreement (this ?Amendment?) is made and entered into as of December 10, 2021 by and between BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and Lance Alstodt (the ?Participant |
|
| March 30, 2022 |
Exhibit 10.23 AMENDMENT NO. 2 TO NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Amendment No. 2 to Non-Qualified Stock Option Award Agreement (this ?Amendment?) is made and entered into as of December 10, 2021 (the ?Effective Date?) by and between BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and Francisc |
|
| March 30, 2022 |
Exhibit 10.20 COMMON STOCK PURCHASE WARRANT BIORESTORATIVE THERAPIES, INC. Warrant Shares: 2,645,000 Initial Exercise Date: November 9, 2021 CUSIP: 090655135 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, CEDE & CO. or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| March 30, 2022 |
Exhibit 10.25 AMENDMENT NO. 1 TO NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Amendment No. 1 to Non-Qualified Stock Option Award Agreement (this ?Amendment?) is made and entered into as of December 10, 2021 by and between BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and Patrick Williams (the ?Particip |
|
| March 30, 2022 |
Exhibit 10.19 AMENDMENT NO. 1 TO NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Amendment No. 1 to Non-Qualified Stock Option Award Agreement (this ?Amendment?) is made and entered into as of December 10, 2021 by and between BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and Francisco Silva (the ?Participa |
|
| March 30, 2022 |
Exhibit 10.16 |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37603 BIORESTORATIVE THERAPIES |
|
| March 30, 2022 |
Exhibit 10.22 AMENDMENT NO. 2 TO NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Amendment No. 2 to Non-Qualified Stock Option Award Agreement (this ?Amendment?) is made and entered into as of December 10, 2021 (the ?Effective Date?) by and between BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and Lance Al |
|
| March 30, 2022 |
EX-10.21 9 ex10-21.htm Exhibit 10.21 COMMON STOCK PURCHASE WARRANT BIORESTORATIVE THERAPIES, INC. Warrant Shares: 1,676,580 Initial Exercise Date: November 9, 2021 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, AUCTUS FUND, LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter |
|
| March 30, 2022 |
Exhibit 10.17 |
|
| March 30, 2022 |
Certificate of Incorporation, as amended Exhibit 3.1 CERTIFICATE OF INCORPORATION OF BIORESTORATIVE THERAPIES, INC. (as amended through November 16, 2021) The undersigned, for the purpose of organizing a corporation under the General Corporation Law of the State of Delaware, certifies: First: The name of the corporation is BioRestorative Therapies, Inc. (hereinafter referred to as the ?Corporation?). Second: The address of the registered |
|
| March 30, 2022 |
Exhibit 10.15 |
|
| March 30, 2022 |
Exhibit 10.26 AMENDMENT NO. 1 TO NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Amendment No. 1 to Non-Qualified Stock Option Award Agreement (this ?Amendment?) is made and entered into as of December 10, 2021 by and between BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and David Rosa (the ?Participant?). |
|
| March 30, 2022 |
Exhibit 10.24 AMENDMENT NO. 1 TO NON-QUALIFIED STOCK OPTION AWARD AGREEMENT UNDER THE BIORESTORATIVE THERAPIES, INC. 2021 STOCK INCENTIVE PLAN This Amendment No. 1 to Non-Qualified Stock Option Award Agreement (this ?Amendment?) is made and entered into as of December 10, 2021 by and between BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), and Nickolay Kukekov (the ?Particip |
|
| March 29, 2022 |
SC 13D/A 1 sc13da6.htm DALE BROADRICK SCHEDULE 13D AMENDMENT 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, $.0001 Par Value (Title of Class of Securities) 090655606 (CUSIP Number) Dale Broadrick 3003 Brick Church Pike Nashville, TN 3720 |
|
| February 14, 2022 |
BioRestorative Therapies, Inc. SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additio |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 090655606 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 2, 2022 |
BRTX / BioRestorative Therapies Inc / Hudson Bay Capital Management LP - BRTX 13G Passive Investment SC 13G 1 brtx13g.htm BRTX 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 090655606 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 3, 2021 BioRestorative Therapies, Inc. (Exact Name of Registrant as Specified in Its Charter) 001-37603 (Commission File Number) Delaware 91-1835664 (State or Other Jurisdict |
|
| December 8, 2021 |
EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this ?Agreement?) is made as of November 4, 2021 (the ?Effective Date?), by and between BioRestorative Therapies, Inc. |
|
| November 23, 2021 |
November 23, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BioRestorative Therapies, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-231079 Ladies and Gentlemen: On April 26, 2019, BioRestorative Therapies, Inc., a Delaware corporation (the ?Company?), filed a Registration Statement |
|
| November 19, 2021 | ||
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2021 BioRestorative Therapies, Inc. (Exact Name of Registrant as Specified in Its Charter) 001-37603 (Commission File Number) Delaware 91-1835664 (State or Other Jurisdic |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioRestorative Therapies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 090655606 (CUSIP Number) November 5, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 16, 2021 |
Altium Capital Management, LP SC 13G EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240. |
|
| November 15, 2021 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2021 BioRestorative Therapies, Inc. (Exact Name of Registrant as Specified in Its Charter) 001-37603 (Commission File Number) Delaware 91-1835664 (State or Other Jurisdict |
|
| November 15, 2021 | ||
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-37603 BIORESTORATIVE T |
|
| November 15, 2021 |
BioRestorative Therapies Announces Closing of $23 Million Public Offering BioRestorative Therapies Announces Closing of $23 Million Public Offering MELVILLE, N. |
|
| November 9, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration No.: 333-258611 Registration No.: 333-260792 PROSPECTUS 2,300,000 Units Each Unit Consisting of One Share of Common Stock (par value $0.0001) and One Warrant to Purchase One Share of Common Stock This is a firm commitment public offering of 2,300,000 units of securities (each, a ?Unit?), each Unit consisting of one share of common stock, $0.0001 par va |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 8, 2021 |
2,300,000 SHARESOF COMMON STOCK AND 2,300,000 WARRANTS OF BIORESTORATIVE THERAPIES, INC. |
